Jun 20 |
SAB Biotherapeutics rebrands as SAB BIO; reaffirms full-year outlook
|
Jun 20 |
SAb Biotherapeutics Rebrands as SAB BIO
|
Jun 18 |
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
|
May 30 |
SAB Biotherapeutics announces departure of CFO
|
May 30 |
SAB Biotherapeutics Announces Departure of Chief Financial Officer
|
May 21 |
SAB Biotherapeutics GAAP EPS of -$0.43 beats by $0.60
|
May 21 |
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
|
May 20 |
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
|
May 6 |
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
|
Apr 16 |
SAB Biotherapeutics Provides SAB-142 Trial Update
|